WO2006029497A1 - Cancerous disease modifying antibodies - Google Patents
Cancerous disease modifying antibodies Download PDFInfo
- Publication number
- WO2006029497A1 WO2006029497A1 PCT/CA2005/000363 CA2005000363W WO2006029497A1 WO 2006029497 A1 WO2006029497 A1 WO 2006029497A1 CA 2005000363 W CA2005000363 W CA 2005000363W WO 2006029497 A1 WO2006029497 A1 WO 2006029497A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- antibody
- antibodies
- cancer
- tumor
- cells
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
- A61K51/1063—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from stomach or intestines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
- A61K51/1051—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from breast, e.g. the antibody being herceptin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
- A61K51/1072—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from the reproductive system, e.g. ovaria, uterus, testes or prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3046—Stomach, Intestines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
Definitions
- This invention relates to the isolation and production of cancerous disease modifying antibodies (CDMAB) and to the use of these CDMAB in therapeutic and diagnostic processes, optionally in combination with one or more chemotherapeutic agents.
- CDMAB cancerous disease modifying antibodies
- the invention further relates to binding assays, which utilize the CDMAB of the instant invention.
- Chemotherapy and radiation treatment cannot be tailored to the patient, and surgery by itself, in most cases is inadequate for producing cures.
- cancerous cells contain antigens that are specific to transformed cells
- monoclonal antibodies can be designed to specifically target transformed cells by binding specifically to these cancer antigens; thus giving rise to the belief that monoclonal antibodies can serve as "Magic Bullets" to eliminate cancer cells.
- CDMAB cancerous disease modifying antibodies
- the cancer patient usually has few options of treatment.
- the regimented approach to cancer therapy has produced improvements in global survival and morbidity rates.
- these improved statistics do not necessarily correlate with an improvement in their personal situation.
- U.S. Patent No. 5,750, 102 discloses a process wherein cells from a patient's tumor are transfected with MHC genes, which may be cloned from cells or tissue from the patient. These transfected cells are then used to vaccinate the patient.
- U.S. Patent No. 4,861,581 discloses a process comprising the steps of obtaining monoclonal antibodies that are specific to an internal cellular component of neoplastic and normal cells of the mammal but not to external components, labeling the monoclonal antibody, contacting the labeled antibody with tissue of a mammal that has received therapy to kill neoplastic cells, and determining the effectiveness of therapy by measuring the binding of the labeled antibody to the internal cellular component of the degenerating neoplastic cells.
- the patentee recognizes that malignant cells represent a convenient source of such antigens.
- U.S. Patent No. 5,171,665 provides a novel antibody and method for its production. Specifically, the patent teaches formation of a monoclonal antibody which has the property of binding strongly to a protein antigen associated with human tumors, e.g. those of the colon and lung, while binding to normal cells to a much lesser degree.
- U.S. Patent No. 5,484,596 provides a method of cancer therapy comprising surgically removing tumor tissue from a human cancer patient, treating the tumor tissue to obtain tumor cells, irradiating the tumor cells to be viable but non-tumorigenic, and using these cells to prepare a vaccine for the patient capable of inhibiting recurrence of the primary tumor while simultaneously inhibiting metastases.
- the patent teaches the development of monoclonal antibodies which are reactive with surface antigens of tumor cells. As set forth at col.4, lines 45 et seq., the patentees utilize autochthonous tumor cells in the development of monoclonal antibodies expressing active specific immunotherapy in human neoplasia.
- U.S. Patent No. 5,693,763 teaches a glycoprotein antigen characteristic of human carcinomas is not dependent upon the epithelial tissue of origin.
- U.S. Patent No. 5,783,186 is drawn to anti-Her2 antibodies, which induce apoptosis in Her2 expressing cells, hybridoma cell lines producing the antibodies, methods of treating cancer using the antibodies and pharmaceutical compositions including said antibodies.
- U.S. Patent No. 5,849,876 describes new hybridoma cell lines for the production of monoclonal antibodies to mucin antigens purified from tumor and non-tumor tissue sources.
- U.S. Patent No. 5,869,268 is drawn to a method for generating a human lymphocyte producing an antibody specific to a desired antigen, a method for producing a monoclonal antibody, as well as monoclonal antibodies produced by the method.
- the patent is particularly drawn to the production of an anti-HD human monoclonal antibody useful for the diagnosis and treatment of cancers.
- U.S. Patent No. 5,869,045 relates to antibodies, antibody fragments, antibody conjugates and single chain immunotoxins reactive with human carcinoma cells.
- antibodies function is two-fold, in that the molecules are reactive with cell membrane antigens present on the surface of human carcinomas, and further in that the antibodies have the ability to internalize within the carcinoma cells, subsequent to binding, making them especially useful for forming antibody-drug and antibody-toxin conjugates. In their unmodified form the antibodies also manifest cytotoxic properties at specific concentrations.
- U.S. Patent No. 5,780,033 discloses the use of autoantibodies for tumor therapy and prophylaxis.
- this antibody is an anti-nuclear autoantibody from an aged mammal.
- the autoantibody is said to be one type of natural antibody found in the immune system. Because the autoantibody comes from "an aged mammal", there is no requirement that the autoantibody actually comes from the patient being treated.
- the patent discloses natural and monoclonal anti-nuclear autoantibody from an aged mammal, and a hybridoma cell line producing a monoclonal anti-nuclear autoantibody.
- tissue sample is understood to mean at least one cell or an aggregate of cells obtained from a mammal. It is well recognized in the art that some amino acid sequence can be varied in a polypeptide without significant effect on the structure or function of the protein.
- modifications in the nucleic or amino acid sequence of the backbone region can generally be tolerated. These include, but are not limited to, substitutions (preferred are conservative substitutions), deletions or additions.
- standard chemotherapeutic modalities e.g. radionuclides
- the CDMAB can also be conjugated to toxins, cytotoxic moieties, enzymes e.g. biotin conjugated enzymes, or hematogenous cells, thereby forming antibody conjugates.
- This application utilizes the method for producing patient specific anti ⁇ cancer antibodies as taught in the '357 patent for isolating hybridoma cell lines which encode for cancerous disease modifying monoclonal antibodies. These antibodies can be made specifically for one tumor and thus make possible the customization of cancer therapy.
- anti-cancer antibodies having either cell- killing (cytotoxic) or cell-growth inhibiting (cytostatic) properties will hereafter be referred to as cytotoxic. These antibodies can be used in aid of staging and diagnosis of a cancer, and can be used to treat tumor metastases.
- the mouse monoclonal antibody 10A304.7 was obtained following immunization of mice with frozen single cell suspensions of the human HT-29 colon cancer cell line that had been grown as a solid tumor in SCID mice. These antibodies can be used in aid of staging and diagnosis of a cancer, and can be used to treat tumor metastases.
- the 10A304.7 antigen was expressed on the cell surface of a broad range of human cell lines from different tissue origins.
- the colon cancer cell line SWl 116, the breast cancer cell lines MDA-MB-231 , MCF-7, the prostate cancer cell line PC-3 and the ovarian cancer cell line OVCAR-3 were the cancer cell lines tested that were susceptible to the cytotoxic effects of 10A304.7 demonstrated in application S.N.
- Xenografts in mice grow as solid tumors developing stroma, central necrosis and neo-vasculature in the same manner as naturally occurring cancers.
- the mammary tumor cell line MDA-MB-231 has been evaluated as an in vivo xenograft model in immunodeficient mice.
- the successful engraftment or 'take-rate' of MDA-MB-231 tumors and the sensitivity of the tumors to standard chemotherapeutic agents have characterized them as suitable models.
- the MDA-MB-231 parental cell line and variants of the cell line have been used successfully in xenograft tumor models to evaluate a wide range of therapeutic agents that are now used as clinical chemotherapeutic agents.
- 10A304.7 prevented tumor growth and reduced tumor burden in a in vivo model of human breast cancer.
- Body weight measured at weekly intervals was a surrogate for health.
- this invention teaches the use of the 10A304.7 antigen as a target for a therapeutic agent, that when administered can reduce the tumor burden of a cancer expressing the antigen in a mammal.
- This invention also teaches the use of CDMAB (10A304.7), and its derivatives, to target its antigen to reduce the tumor burden of a cancer expressing the antigen in a mammal.
- this invention also teaches the use of detecting the 10A304.7 antigen in cancerous cells that can be useful for the diagnosis, prediction of therapy, and prognosis of mammals bearing tumors that express this antigen. The prospect of individualized anti-cancer treatment will bring about a change in the way a patient is managed.
- a likely clinical scenario is that a tumor sample is obtained at the time of presentation, and banked. From this sample, the tumor can be typed from a panel of pre-existing cancerous disease modifying antibodies.
- the patient will be conventionally staged but the available antibodies can be of use in further staging the patient.
- the patient can be treated immediately with the existing antibodies and/or a panel of antibodies specific to the tumor can be produced either using the . methods outlined herein or through the use of phage display libraries in conjunction with the screening methods herein disclosed. All the antibodies generated will be added to the library of anti ⁇ cancer antibodies since there is a possibility that other tumors can bear some of the same epitopes as the one that is being treated.
- the antibodies produced according to this method may be useful to treat cancerous disease in any number of patients who have cancers that bind to these antibodies.
- the process of generating specific antibodies to the tumor can be repeated for re- treatment.
- the anti-cancer antibodies can be conjugated to red blood cells obtained from that patient and re-infused for treatment of metastases.
- metastatic cancers There have been few effective treatments for metastatic cancer and metastases usually portend a poor outcome resulting in death.
- metastatic cancers are usually well vascularized and the delivery of anti-cancer antibodies by red blood cells can have the effect of concentrating the antibodies at the site of the tumor.
- Even prior to metastases most cancer cells are dependent on the host's blood supply for their survival and an anti-cancer antibody conjugated to red blood cells can be effective against in situ tumors as well.
- the antibodies may be conjugated to other hematogenous cells, e.g. lymphocytes, macrophages, monocytes, natural killer cells, etc.
- hematogenous cells e.g. lymphocytes, macrophages, monocytes, natural killer cells, etc.
- lymphocytes e.g. lymphocytes, macrophages, monocytes, natural killer cells, etc.
- CDC complement-dependent cytotoxicity
- murine IgM and IgG2a antibodies can activate human complement by binding the C-I component of the complement system thereby activating the classical pathway of complement activation which can lead to tumor lysis.
- the most effective complement activating antibodies are generally IgM and IgGl.
- Murine antibodies of the IgG2a and IgG3 isotype are effective at recruiting cytotoxic cells that have Fc receptors which will lead to cell killing by monocytes, macrophages, granulocytes and certain lymphocytes.
- Human antibodies of both the IgGl and IgG3 isotype mediate ADCC.
- Another possible mechanism of antibody mediated cancer killing may be through the use of antibodies that function to catalyze the hydrolysis of various chemical bonds in the cell membrane and its associated glycoproteins or glycolipids, so-called catalytic antibodies.
- the first is the use of antibodies as a vaccine to induce the body to produce an immune response against the putative antigen that resides on the cancer cell.
- the second is the use of antibodies to target growth receptors and interfere with their function or to down regulate that receptor so that effectively its function is lost.
- RECIST criteria Clinical criteria for such evaluation have been promulgated by Response Evaluation Criteria in Solid Tumors Working Group, a group of international experts in cancer. Drugs with a demonstrated effect on tumor burden, as shown by objective responses according to RECIST criteria, in comparison to the appropriate control group tend to, ultimately, produce direct patient benefit.
- tumor burden is generally more straightforward to assess and document.
- pre-clinical studies can be translated to the clinical setting, drugs that produce prolonged survival in pre-clinical models have the greatest anticipated clinical utility. Analogous to producing positive responses to clinical treatment, drugs that reduce tumor burden in the pre-clinical setting may also have significant direct impact on the disease.
- CDMAB cytotoxicity is a function of their ability to catalyze hydrolysis of cellular chemical bonds.
- a still further objective of the instant invention is to produce CDMAB which are useful in a binding assay for the diagnosis, prognosis, and monitoring of cancer.
- Figure 1 Representative FACS histograms of 10A304.7, isotype control and anti-EGFR antibodies directed against several cancer and non-cancer cell lines.
- Figure 2 Effect of 10A304.7 on tumor growth in a MDA-MB-231 breast cancer model.
- the dashed line indicates the period during which the antibody was administered.
- Data points represent the mean +/- SEM.
- Figure 3 Effect of 10A304.7 on body weight in a MDA-MB-231 breast cancer model. Data points represent the mean +/- SEM.
- the hybridoma cell line 10A304.7 was deposited, in accordance with the Budapest Treaty, with the American Type Culture Collection, 10801 University Boulevard., Manassas, VA 20110-2209 on March 19, 2003, under Accession Number PTA-5065.
- the depositors assure that all restrictions imposed on the availability to the public of the deposited materials will be irrevocably removed upon the granting of a patent.
- 10A304.7 monoclonal antibody was produced by culturing the hybridoma in CL-1000 flasks (BD Biosciences, Oakville, ON) with collections and reseeding occurring twice/week and with purification according to standard antibody purification procedures with Protein G Sepharose 4 Fast Flow (Amersham Biosciences, Baie d'Urfe, QC). As previously described in S.N.
- 10/413,755, 10A304.7 was compared to a number of both positive (anti-Fas (EOS9.1, IgM, kappa, 20 mg/mL, eBioscience, San Diego, CA), anti-Her2/neu (IgGl, kappa, 10 mg/mL, Inter Medico, Markham, ON), anti- EGFR (C225, IgGl, kappa, 5 mg/mL, Cedarlane, Hornby, ON), Cycloheximide (100 mM, Sigma, Oakville, ON), and NaN 3 (0.1%, Sigma, Oakville, ON)) and negative (107.3 (anti- TNP, IgGl, kappa, 20 mg/mL, BD Biosciences, Oakville, ON), MPC-I l (antigenic specificity unknown, IgG2b, kappa, 20 mg/mL), IgG Buffer (2%)) controls in a cytotoxicity assay (Table 1).
- EOS9.1 IgM,
- MDA-MB-231 (MB-231), MCF-7), colon cancer (Caco-2, DLD-I, Lovo, HT-29, SWl 116, SW620), ovarian cancer (OVCAR), pancreatic cancer (BxPC-3), prostate cancer (PC-3), and non-cancer (CCD 27sk, Hs888.Lu) cell lines were tested (all from the ATCC, Manassas, VA).
- the Live/Dead cytotoxicity assay was obtained from Molecular Probes (Eugene,OR). The assays were performed according to the manufacturer's instructions with the changes outlined below. Cells were plated before the assay at the predetermined appropriate density.
- the plates were read in a Perkin-Elmer HTS7000 fluorescence plate reader and the data was analyzed in Microsoft Excel and the results were tabulated in Table 1.
- the data represented an average of four experiments tested in triplicate and presented qualitatively in the following fashion: 4/4 experiments with 15% cytotoxicity above background (++++), 2/4 experiments with 15% cytotoxicity above background (+++), at least 2/4 experiments with 10-15% cytotoxicity above background (++), and at least 2/4 experiments with 8- 10% cytotoxicity above background.
- Unmarked cells in Table 1 represented inconsistent or effects less than the threshold cytotoxicity.
- the 10A304.7 antibody produced 35% of the cytotoxic effect of the well-described anti-EGFR antibody C225, which induced 31 % cytotoxicity in the SWl 116 colon cell line.
- 10A304.7 induced significantly higher cytotoxicity against other cancer cells, compared with C225, including the breast cancer cell lines MDA-MB-231 (111%) and MCF-7 (850%), the prostate cancer cell line PC-3 (375%), and the ovarian cancer cell line OVCAR (667%).
- 10A304.7 did not produce cytotoxicity against a number of non-cancer cells such as CCD 27sk or Hs888.Lu, indicating that the antibody has functional specificity towards various cancer cells.
- the chemical cytotoxic agents induced their expected cytotoxicity while a number of other antibodies which were included for comparison also performed as expected given the limitations of biological cell assays.
- the cells were resuspended in Dulbecco's phosphate buffered saline containing MgCl 2- CaCl 2 and 25% fetal bovine serum at 4 0 C (wash media) and counted, aliquoted to appropriate cell density, spun down to pellet the cells and resuspended in staining media (DPBS containing MgCl 2 CaCl 2 and 2% fetal bovine serum) at 4°C in the presence of test antibody ( 10A304.7) or control antibodies (isotype control, anti-EGF-R, or anti-Fas) at 20 micrograms/mL on ice for 30 minutes.
- test antibody 10A304.7
- control antibodies isotype control, anti-EGF-R, or anti-Fas
- the cells Prior to the addition of Alexa Fluor 488-conjugated secondary antibody the cells were washed once with wash media. The Alexa Fluor 488- conjugated antibody in staining media was then added for 20 minutes. The cells were then washed for the final time and resuspended in staining media containing 1 microgram/mL propidium iodide. Flow cytometric acquisition of the cells was assessed by running samples on a FACScan using the CellQuest software (BD Biosciences). The forward (FSC) and side scatter (SSC) of the cells were set by adjusting the voltage and amplitude gains on the FSC and SSC detectors.
- FSC forward
- SSC side scatter
- the detectors for the three fluorescence channels (FL 1 , FL2, and FL3) were adjusted by running cells stained with purified isotype control antibody followed by Alexa Fluor 488-conjugated secondary antibody such that cells had a uniform speak with a median fluorescent intensity of approximately 1-5 units.
- Live cells were acquired by gating for FSC and propidium iodide exclusion. For each sample, approximately 10,000 live cells were acquired for analysis and the results presented in Table 2.
- Table 2 tabulated the mean fluorescence intensity fold increase above isotype control and is presented qualitatively as: less than 3 to 5 (+); 5 to 25 (++); 25 to 50 (+++); and above 50 (++++).
- Representative histograms of 10A304.7 antibody were compiled for Figure 1 and evidence of the binding characteristics, inclusive of illustrated bimodal peaks in some cases.
- 10A304.7 non-specifically bound to all cell lines, including high binding to the non-cancer cells CCD 27sk and Hs888.Lu, but the degree of binding differed between the various cell lines. 10A304.7 thus selectively bound to the cell lines at different levels. Results from Tables 1 and 2 indicate that the binding of 10A304.7 to tumor cells is necessary for antibody-mediated cytotoxicity but it is not sufficient in triggering this event.
- mice 4 to 8 week old female SCID mice were implanted with 5 million MDA-MB-231 human breast cancer cells (MB-231) in 100 microlitres saline injected subcutaneously in the scruff of the neck. The mice were randomly divided into 2 treatment groups of 5. On the day after implantation, 20 mg/kg of 10A304.7 test antibody or isotype control antibody (known not to bind MB-231 cells) was administered intraperitoneally at a volume of 300 microliters after dilution from the stock concentration with a diluent that contained 2.7 mM KCl, 1 mM KH 2 PO 4 137 mM NaCl and 20 mM Na 2 HPO 4 .
- 10A304.7 test antibody or isotype control antibody known not to bind MB-231 cells
- the antibodies were then administered once per week for a period of 7 weeks in the same fashion. Tumor growth was measured about every seventh day with calipers for up to 10 weeks or until individual animals reached the Canadian Council for Animal Care (CCAC) end-points. Body weights of the animals were recorded for the duration of the study. At the end of the study all animals were euthanised according to CCAC guidelines.
- CCAC Canadian Council for Animal Care
- 10 A304.7 prevented tumor growth and reduced tumor burden in a preventative in vivo model of human breast cancer.
- Body weight measured at weekly intervals was a surrogate for well-being and failure to thrive.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Oncology (AREA)
- Cell Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Optics & Photonics (AREA)
- Biochemistry (AREA)
- Reproductive Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Description
Claims
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2005284618A AU2005284618A1 (en) | 2004-09-15 | 2005-03-10 | Cancerous disease modifying antibodies |
NZ553855A NZ553855A (en) | 2004-09-15 | 2005-03-10 | Monoclonal antibodies expressed by ATCC PTA-5065 for the treatment of cancer |
CA002579900A CA2579900A1 (en) | 2004-09-15 | 2005-03-10 | Cancerous disease modifying antibodies |
EP05714603A EP1796721A4 (en) | 2004-09-15 | 2005-03-10 | Cancerous disease modifying antibodies |
JP2007530554A JP2008513361A (en) | 2004-09-15 | 2005-03-10 | Cancerous disease modifying antibodies |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/944,664 US7195764B2 (en) | 2003-04-14 | 2004-09-15 | Cancerous disease modifying antibodies |
US10/944,664 | 2004-09-15 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2006029497A1 true WO2006029497A1 (en) | 2006-03-23 |
Family
ID=36059657
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CA2005/000363 WO2006029497A1 (en) | 2004-09-15 | 2005-03-10 | Cancerous disease modifying antibodies |
Country Status (8)
Country | Link |
---|---|
US (1) | US7195764B2 (en) |
EP (1) | EP1796721A4 (en) |
JP (1) | JP2008513361A (en) |
CN (1) | CN101084013A (en) |
AU (1) | AU2005284618A1 (en) |
CA (1) | CA2579900A1 (en) |
NZ (1) | NZ553855A (en) |
WO (1) | WO2006029497A1 (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2537245C2 (en) * | 2006-10-12 | 2014-12-27 | Чугаи Сейяку Кабусики Кайся | Diagnosing and treating malignant tumour with using anti-ereg antibody |
US9556264B2 (en) | 2011-12-28 | 2017-01-31 | Chugai Seiyaku Kabushiki Kaisha | Humanized anti-epiregulin antibody, and cancer therapeutic agent comprising said antibody as active ingredient |
US10005832B2 (en) | 2009-05-29 | 2018-06-26 | Chugai Seiyaku Kabushiki Kaisha | Method for treating a disease originated from receptor activation by EREG and TGFα |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20080025977A1 (en) * | 2003-04-14 | 2008-01-31 | Arius Research, Inc. | Cytotoxicity mediation of cells evidencing surface expression of CD59 |
US20080213169A1 (en) * | 2003-04-14 | 2008-09-04 | Arius Research, Inc. | Cytotoxicity mediation of cells evidencing surface expression of CD59 |
US7195764B2 (en) * | 2003-04-14 | 2007-03-27 | Arius Research Inc. | Cancerous disease modifying antibodies |
US20060140963A1 (en) * | 2003-04-14 | 2006-06-29 | Arius Research, Inc. | Cytotoxicity mediation of cells evidencing surface expression of CD59 |
CN101724072B (en) * | 2008-10-27 | 2013-10-09 | 谷为岳 | Sequence and application thereof of anti-tumor monoclonal antibody |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6180357B1 (en) * | 1999-10-08 | 2001-01-30 | Arius Research, Inc. | Individualized patient-specific anti-cancer antibodies |
WO2003055515A1 (en) * | 2001-12-21 | 2003-07-10 | Arius Research, Inc. | Individualized anti-cancer antibodies |
US6657048B2 (en) * | 1999-10-08 | 2003-12-02 | Arius Research, Inc. | Individualized anti-cancer antibodies |
WO2004089989A1 (en) * | 2003-04-14 | 2004-10-21 | Arius Research, Inc. | Cancerous disease modifying antibodies |
US20050053609A1 (en) * | 2003-04-14 | 2005-03-10 | Arius Research, Inc. | Cancerous disease modifying antibodies |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4828991A (en) | 1984-01-31 | 1989-05-09 | Akzo N.V. | Tumor specific monoclonal antibodies |
AU613590B2 (en) | 1986-11-19 | 1991-08-08 | Bristol-Myers Squibb Company | Hybridomas producing monoclonal antibodies to new mucin epitopes |
US4861581A (en) | 1986-12-05 | 1989-08-29 | Cancer Biologics, Inc. | Detection of necrotic malignant tissue and associated therapy |
US5171665A (en) | 1989-04-17 | 1992-12-15 | Oncogen | Monoclonal antibody to novel antigen associated with human tumors |
US6020145A (en) | 1989-06-30 | 2000-02-01 | Bristol-Myers Squibb Company | Methods for determining the presence of carcinoma using the antigen binding region of monoclonal antibody BR96 |
EP0539970B1 (en) | 1991-10-30 | 1999-05-26 | Idemitsu Kosan Company Limited | Methods for producing human lymphocytes and human monoclonal antibodies, and human monoclonal antibodies produced thereby |
IL105008A0 (en) | 1992-03-13 | 1993-07-08 | Yeda Res & Dev | Double transfectants of mhc genes as cellular vaccines for immunoprevention of tumor metastasis |
US5545532A (en) | 1993-02-05 | 1996-08-13 | Epigen, Inc. | Human carcinoma antigen (HCA), HCA antibodies, HCA immunoassays and methods of imaging |
JPH10505819A (en) | 1994-06-24 | 1998-06-09 | ヴラディミール ピー. トーチリン | Use of autoantibodies for treatment and prevention of tumors |
US5783186A (en) | 1995-12-05 | 1998-07-21 | Amgen Inc. | Antibody-induced apoptosis |
US7256271B2 (en) * | 2003-01-21 | 2007-08-14 | Arius Research Inc. | Cancerous disease modifying antibodies |
US20040001789A1 (en) * | 1999-10-08 | 2004-01-01 | Young David S. F. | Cytotoxicity mediation of cells evidencing surface expression of gp96 or precursors thereof |
US7252821B2 (en) * | 1999-10-08 | 2007-08-07 | Arius Research Inc. | Cancerous disease modifying antibodies |
US6824780B1 (en) * | 1999-10-29 | 2004-11-30 | Genentech, Inc. | Anti-tumor antibody compositions and methods of use |
US7361343B2 (en) * | 2003-01-21 | 2008-04-22 | Arius Research Inc. | Cytotoxicity mediation of cells evidencing surface expression of CD63 |
US7393531B2 (en) * | 2003-01-21 | 2008-07-01 | Arius Research Inc. | Cytotoxicity mediation of cells evidencing surface expression of MCSP |
US7468254B2 (en) * | 2003-01-21 | 2008-12-23 | Arius Research Inc. | Cytotoxicity mediation of cells evidencing surface expression of MCSP |
US7361342B2 (en) * | 2003-01-21 | 2008-04-22 | Arius Research Inc. | Cancerous disease modifying antibodies |
-
2004
- 2004-09-15 US US10/944,664 patent/US7195764B2/en not_active Expired - Fee Related
-
2005
- 2005-03-10 NZ NZ553855A patent/NZ553855A/en unknown
- 2005-03-10 JP JP2007530554A patent/JP2008513361A/en active Pending
- 2005-03-10 CN CNA200580039082XA patent/CN101084013A/en active Pending
- 2005-03-10 EP EP05714603A patent/EP1796721A4/en not_active Withdrawn
- 2005-03-10 WO PCT/CA2005/000363 patent/WO2006029497A1/en active Application Filing
- 2005-03-10 CA CA002579900A patent/CA2579900A1/en not_active Withdrawn
- 2005-03-10 AU AU2005284618A patent/AU2005284618A1/en not_active Abandoned
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6180357B1 (en) * | 1999-10-08 | 2001-01-30 | Arius Research, Inc. | Individualized patient-specific anti-cancer antibodies |
US6657048B2 (en) * | 1999-10-08 | 2003-12-02 | Arius Research, Inc. | Individualized anti-cancer antibodies |
WO2003055515A1 (en) * | 2001-12-21 | 2003-07-10 | Arius Research, Inc. | Individualized anti-cancer antibodies |
WO2004089989A1 (en) * | 2003-04-14 | 2004-10-21 | Arius Research, Inc. | Cancerous disease modifying antibodies |
US20050053609A1 (en) * | 2003-04-14 | 2005-03-10 | Arius Research, Inc. | Cancerous disease modifying antibodies |
Non-Patent Citations (2)
Title |
---|
DESOUSA HITZLER ET AL: "Functional approach to therapeutic antibody generation yields antibodies effective against relevant tumor antigens", CLINICAL CANCER RESEARCH, vol. 9, no. 16, 1 December 2003 (2003-12-01), pages - 6187, XP008111641 * |
ISHIZUKA ET AL: "Antitumor activity of murine monoclonal antibody NCC-ST-421 on human cancer cells by inducing apoptosis", ANTICANCER RESEARCH, vol. 18, 1998, pages 2513 - 2518, XP001156059 * |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2537245C2 (en) * | 2006-10-12 | 2014-12-27 | Чугаи Сейяку Кабусики Кайся | Diagnosing and treating malignant tumour with using anti-ereg antibody |
US9017684B2 (en) | 2006-10-12 | 2015-04-28 | Chugai Seiyaku Kabushiki Kaisha | Diagnosis and treatment of cancer using anti-EREG antibody |
US10005832B2 (en) | 2009-05-29 | 2018-06-26 | Chugai Seiyaku Kabushiki Kaisha | Method for treating a disease originated from receptor activation by EREG and TGFα |
US9556264B2 (en) | 2011-12-28 | 2017-01-31 | Chugai Seiyaku Kabushiki Kaisha | Humanized anti-epiregulin antibody, and cancer therapeutic agent comprising said antibody as active ingredient |
Also Published As
Publication number | Publication date |
---|---|
CN101084013A (en) | 2007-12-05 |
EP1796721A4 (en) | 2009-03-04 |
NZ553855A (en) | 2009-02-28 |
EP1796721A1 (en) | 2007-06-20 |
JP2008513361A (en) | 2008-05-01 |
US20050053609A1 (en) | 2005-03-10 |
US7195764B2 (en) | 2007-03-27 |
AU2005284618A1 (en) | 2006-03-23 |
CA2579900A1 (en) | 2006-03-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7442776B2 (en) | Cancerous disease modifying antibodies | |
US7399835B2 (en) | Cancerous disease modifying antibodies | |
US7189825B2 (en) | Cancerous disease modifying antibodies | |
US7348413B2 (en) | Cancerous disease modifying antibodies | |
WO2006029497A1 (en) | Cancerous disease modifying antibodies | |
US7361342B2 (en) | Cancerous disease modifying antibodies | |
US6794494B1 (en) | Cancerous disease modifying antibodies | |
WO2005111198A1 (en) | Cancerous disease modifying antibodies | |
WO2005012361A2 (en) | Antibodies raised against colon carcinomas | |
US20040141914A1 (en) | Cancerous disease modifying antibodies | |
WO2007101331A1 (en) | Cancerous disease modifying antibodies for diagnostic and therapeutic use in breast and prostate cancer |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2579900 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007530554 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 553855 Country of ref document: NZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2005284618 Country of ref document: AU |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2005714603 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2005284618 Country of ref document: AU Date of ref document: 20050310 Kind code of ref document: A |
|
WWP | Wipo information: published in national office |
Ref document number: 2005284618 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 200580039082.X Country of ref document: CN |
|
WWP | Wipo information: published in national office |
Ref document number: 2005714603 Country of ref document: EP |